Plasma equipment manufacturer Plasmap to expand Japanese and US markets = South Korea

Plasma equipment manufacturer Plasmapp recently announced a 1.4 billion won (approximately 1.5 billion 50.5 million yen) contract for implant surface treatment equipment with Japanese distribution company Yoshida.
We have concluded a supply contract for Actilink Reborn and have delivered the first batch. Prior to this, the company entered into a product supply agreement worth 16.4 billion won (approximately 1.8 billion yen) with Japanese distribution company Nextera.
had entered into a contract. The company aims to expand its base by setting 2023 as the first year for its expansion into Japan. The company will also expand into the U.S. veterinary medical device market. Current trends in the U.S. veterinary market
We are currently in discussions regarding delivery with at least three of the five major telecommunications companies. A company official said, ``Other than us, there are only three companies in the world that have received certification from the U.S. Food and Drug Administration for sterilization equipment.''
Beta. In the future, we aim to increase sales and quickly return to operating profit. According to the Korea IR Council's Corporate Research Center, the company had sales of 17.6 billion won (approximately 1,941.28 million yen) this year.
), the operating loss is expected to reach 15.5 billion won (approximately 1.7 billion yen). Kim Kyung-min, a researcher at the center, said, ``Plasmap has an order backlog of 155 billion won (approximately 17.9 billion won) in the first half of this year.
6.5 million yen). Considering that approximately 70% of the remaining order backlog is from customers in North America and Europe, we can expect an increase in sales and a reduction in operating losses."